The Target Differences of Anti-Tumorigenesis Potential of Curcumin and Its Analogues Against HER-2 Positive and Triple-Negative Breast Cancer Cells

Overview

Journal Adv Pharm Bull

Date 2021 Mar 22

PMID 33747866

Citations 11

Authors

Edy Meiyanto

Ulfatul Husnaa

Ria Fajarwati Kastian

Herwandhani Putri

Yonika Arum Larasati

Annisa Khumaira

Dyaningtyas Dewi Putri Pamungkas

Riris Istighfari Jenie

Masashi Kawaichi

Beni Lestari

Takashi Yokoyama

Jun-Ya Kato

Affiliations

Soon will be listed here.

Abstract

The current study aims to evaluate the cytotoxic and cell migration effects of synthetic curcumin and its analogues on HER2 and nuclear factor kappa B (NFκB) pathways, as well as the in vivo inhibitory effect on cancer growth of metastatic breast cancer. Cell viability, protein expression, and protein localization were determined using MTT assay, western blotting, and immunofluorescence, respectively. Meanwhile, scratch wound healing assay and gelatin zymography were conducted to investigate the metastasis inhibitory effect. The anti-tumor ability was evaluated in xenograft mouse model using triple-negative breast cancer (TNBC) cells. Curcumin, PGV-0, and PGV-1 exhibited cytotoxic effect against HER2-overexpressing breast cancer cells. Although PGV-1 showed the best activity in the single cytotoxic assay, curcumin showed the strongest synergism with doxorubicin. Curcumin and PGV-0 inhibited membrane localization of HER2. In contrast, PGV-1 neither inhibited localization nor decreased the expression of HER2, nonetheless showed the most potent inhibition against nuclear localization of p65 indicating the different mechanisms of curcumin, PGV-0, and PGV-1. Regarding cancer metastasis, curcumin and PGV-1 showed inhibitory activities against cell migration and inhibited MMP-2 and MMP-9 protein expression. Lastly, PGV-1 was more potent compared to curcumin to suppress the tumor formation of metastatic breast cancer xenograft model in nude mice. Overall, our study strengthens the potency of curcumin analogue, PGV-1, for treating several types of cancer, including metastatic breast cancer.

Citing Articles

PGV-1 Causes Disarrangement of Spindle Microtubule Organization Resulting in Aberrant Mitosis in HLF and HuH6 Cells Associated with Altered MYCN Status.

Nugraheni N, Zulfin U, Lestari B, Hapsari N, Ikawati M, Utomo R Adv Pharm Bull. 2024; 14(3):665-674.

PMID: 39494255 PMC: 11530888. DOI: 10.34172/apb.2024.058.

Pentagamavunone-1 inhibits aggressive breast cancer cell proliferation through mitotic catastrophe and ROS-mediated activities: and studies.

Novitasari D, Nakamae I, Jenie R, Yoneda-Kato N, Kato J, Meiyanto E Saudi Pharm J. 2023; 32(1):101892.

PMID: 38146327 PMC: 10749286. DOI: 10.1016/j.jsps.2023.101892.

Tumour-suppressive effects of curcumin analogs CCA-1.1 and Pentagamavunone-1 in colon cancer: and studies.

Wulandari F, Ikawati M, Widyarini S, Kirihata M, Novitasari D, Kato J J Adv Pharm Technol Res. 2023; 14(4):317-324.

PMID: 38107450 PMC: 10723174. DOI: 10.4103/JAPTR.JAPTR_315_23.

In vitro synergistic effect of hesperidin and doxorubicin downregulates epithelial-mesenchymal transition in highly metastatic breast cancer cells.

Amalina N, Salsabila I, Zulfin U, Jenie R, Meiyanto E J Egypt Natl Canc Inst. 2023; 35(1):6.

PMID: 36967442 DOI: 10.1186/s43046-023-00166-3.

Modified Curcumins as Potential Drug Candidates for Breast Cancer: An Overview.

Flint A, Hansen D, Brown L, Stewart L, Ortiz E, Panda S Molecules. 2022; 27(24).

PMID: 36558022 PMC: 9784715. DOI: 10.3390/molecules27248891.

References

Mahavorasirikul W, Viyanant V, Chaijaroenkul W, Itharat A, Na-Bangchang K . Cytotoxic activity of Thai medicinal plants against human cholangiocarcinoma, laryngeal and hepatocarcinoma cells in vitro. BMC Complement Altern Med. 2010; 10:55. PMC: 2956707. DOI: 10.1186/1472-6882-10-55. View

Pulaski B, Ostrand-Rosenberg S . Mouse 4T1 breast tumor model. Curr Protoc Immunol. 2008; Chapter 20:Unit 20.2. DOI: 10.1002/0471142735.im2002s39. View

Chen F, Demers L, Shi X . Upstream signal transduction of NF-kappaB activation. Curr Drug Targets Inflamm Allergy. 2003; 1(2):137-49. DOI: 10.2174/1568010023344706. View

Bravo-Cordero J, Hodgson L, Condeelis J . Directed cell invasion and migration during metastasis. Curr Opin Cell Biol. 2012; 24(2):277-83. PMC: 3320684. DOI: 10.1016/j.ceb.2011.12.004. View

Sirkisoon S, Carpenter R, Rimkus T, Miller L, Metheny-Barlow L, Lo H . EGFR and HER2 signaling in breast cancer brain metastasis. Front Biosci (Elite Ed). 2015; 8(2):245-63. PMC: 4809353. DOI: 10.2741/E765. View

Nakamae I, Morimoto T, Shima H, Shionyu M, Fujiki H, Yoneda-Kato N . Curcumin Derivatives Verify the Essentiality of ROS Upregulation in Tumor Suppression. Molecules. 2019; 24(22). PMC: 6891586. DOI: 10.3390/molecules24224067. View

Lestari B, Nakamae I, Yoneda-Kato N, Morimoto T, Kanaya S, Yokoyama T . Pentagamavunon-1 (PGV-1) inhibits ROS metabolic enzymes and suppresses tumor cell growth by inducing M phase (prometaphase) arrest and cell senescence. Sci Rep. 2019; 9(1):14867. PMC: 6795878. DOI: 10.1038/s41598-019-51244-3. View

Duru N, Candas D, Jiang G, Li J . Breast cancer adaptive resistance: HER2 and cancer stem cell repopulation in a heterogeneous tumor society. J Cancer Res Clin Oncol. 2013; 140(1):1-14. PMC: 3889683. DOI: 10.1007/s00432-013-1494-1. View

Hong R, Spohn W, Hung M . Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. Clin Cancer Res. 1999; 5(7):1884-91. View

10.

Ithimakin S, Day K, Malik F, Zen Q, Dawsey S, Bersano-Begey T . HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res. 2013; 73(5):1635-46. PMC: 3600586. DOI: 10.1158/0008-5472.CAN-12-3349. View

11.

Faltus T, Yuan J, Zimmer B, Kramer A, Loibl S, Kaufmann M . Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. Neoplasia. 2005; 6(6):786-95. PMC: 1531682. DOI: 10.1593/neo.04313. View

12.

Harper K, Sosa M, Entenberg D, Hosseini H, Cheung J, Nobre R . Mechanism of early dissemination and metastasis in Her2 mammary cancer. Nature. 2016; 540(7634):588-592. PMC: 5471138. DOI: 10.1038/nature20609. View

13.

Meiyanto E, Pamungkas Putri D, Asmah Susidarti R, Murwanti R, Sardjiman , Fitriasari A . Curcumin and its analogues (PGV-0 and PGV-1) enhance sensitivity of resistant MCF-7 cells to doxorubicin through inhibition of HER2 and NF-kB activation. Asian Pac J Cancer Prev. 2014; 15(1):179-84. DOI: 10.7314/apjcp.2014.15.1.179. View

14.

Bailey S, Miron P, Choi Y, Kochupurakkal B, Maulik G, Rodig S . NF-κB activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth. Mol Cancer Res. 2013; 12(3):408-420. PMC: 4026253. DOI: 10.1158/1541-7786.MCR-13-0206-T. View

15.

Gupta P, Srivastava S . HER2 mediated de novo production of TGFβ leads to SNAIL driven epithelial-to-mesenchymal transition and metastasis of breast cancer. Mol Oncol. 2014; 8(8):1532-47. PMC: 4252481. DOI: 10.1016/j.molonc.2014.06.006. View

16.

Deng Y, Verron E, Rohanizadeh R . Molecular Mechanisms of Anti-metastatic Activity of Curcumin. Anticancer Res. 2016; 36(11):5639-5647. DOI: 10.21873/anticanres.11147. View

17.

Weaver A . Invadopodia: specialized cell structures for cancer invasion. Clin Exp Metastasis. 2006; 23(2):97-105. DOI: 10.1007/s10585-006-9014-1. View

18.

Larasati Y, Yoneda-Kato N, Nakamae I, Yokoyama T, Meiyanto E, Kato J . Curcumin targets multiple enzymes involved in the ROS metabolic pathway to suppress tumor cell growth. Sci Rep. 2018; 8(1):2039. PMC: 5794879. DOI: 10.1038/s41598-018-20179-6. View

19.

Reynolds C, Maurer B . Evaluating response to antineoplastic drug combinations in tissue culture models. Methods Mol Med. 2005; 110:173-83. DOI: 10.1385/1-59259-869-2:173. View

20.

Meiyanto E, Septisetyani E, Larasati Y, Kawaichi M . Curcumin Analog Pentagamavunon-1 (PGV-1) Sensitizes Widr Cells to 5-Fluorouracil through Inhibition of NF-κB Activation. Asian Pac J Cancer Prev. 2018; 19(1):49-56. PMC: 5844636. DOI: 10.22034/APJCP.2018.19.1.49. View